Laurus Labs Limited announced its audited consolidated financial results for FY26, demonstrating exceptional performance with net profit reaching ₹890.14 crore compared to ₹358.34 crore in the previous fiscal year, representing a remarkable 148% growth. The company also delivered strong revenue growth of 23% and significantly improved EBITDA margins to 26.8%. The financial results were published in "Business Standard" (English) and "Prajasakti" (Telugu) on May 01, 2026, pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Outstanding Financial Performance

The company delivered robust growth across all key financial metrics for both the full year and fourth quarter. For FY26, revenues reached ₹6,812.90 crore, representing substantial growth from ₹5,553.96 crore in FY25. The company achieved EBITDA of ₹1,826 crore with margins of 26.8%, marking a significant improvement of 6.7 percentage points over the previous year.

Strong Divisional Performance

The CDMO division reported exceptional growth with revenues of ₹2,080 crore in FY26, representing 36% growth from the previous year. Small molecules business within CDMO achieved ₹1,896 crore revenue with 38% growth, driven by late-stage pipeline projects and commercial NCE API supplies. The Bio division delivered ₹184 crore revenue with 15% growth for the full year.

Dividend Declaration and Corporate Actions

The Board of Directors at their meeting held on April 30, 2026, approved the payment of 2nd Interim Dividend of ₹1.20 per equity share of ₹2 each for FY26. Pursuant to Regulation 42 of the SEBI Listing Regulations, the company has fixed May 8, 2026 as the record date for determining shareholder eligibility, with dividend payment scheduled on or after May 20, 2026. The 21st Annual General Meeting has been scheduled for July 2, 2026, through video conferencing.

Management Commentary and Outlook

Dr. Satyanarayana Chava, Founder & Chief Executive Officer, highlighted the company's accelerated performance backed by successful commercial supplies for NCE programs and sustained leadership in the anti-retroviral segment. V V Ravi Kumar, Executive Director & Chief Financial Officer, emphasized the strong operating performance with gross margins improving by over 5 percentage points to 60.4% due to favorable CDMO mix. The company maintains over 125 active pipeline projects across human health, animal health, and crop science, with continued CAPEX investments planned for FY27-28 to support growth projects across multiple technologies.

The Board of Directors of Laurus Labs at their meeting held on April 30, 2026, approved several significant corporate decisions including director appointments and retirement, investment in joint venture, and voluntary closure of its German subsidiary. The meeting commenced at 2.00 p.m. and concluded at 3.00 p.m.

Director Appointments and Retirement

On the recommendation of the Nomination and Remuneration Committee, the Board approved and recommended to shareholders the appointment of Dr. Shekhar Chintamani Mande (DIN: 10083454) and Ms. Sutapa Banerjee (DIN: 02844650) as Independent Directors for a term of five consecutive years effective from July 02, 2026. Both appointees are not related to any Directors or Key Managerial Personnel of the Company and are not debarred from holding the office of Director.

Dr. Shekhar Chintamani Mande is a structural and computational biologist, distinguished professor at Savitribai Phule Pune University, and former Director General of CSIR. He was awarded the Shanti Swarup Bhatnagar Prize in 2005 and currently serves as an Independent Director on the board of Tata Steel Limited. Ms. Sutapa Banerjee has over three decades of experience in financial services, including leadership roles at ANZ Grindlays, ABN AMRO, and Ambit Private Wealth. She was voted one of the 'Top 20 Global Rising Stars of Wealth Management' by the Institutional Investor Group in 2007.

The Board also took note of the retirement of Mrs. Aruna Bhinge (DIN: 07474950) as Independent Director effective from close of business hours on July 6, 2026, after completing her second term from July 7, 2021 to July 6, 2026.

Investment in KRKA Pharma Joint Venture

The Board approved an investment of up to EUR 9,800,000 in KRKA Pharma Private Limited, a joint venture incorporated in April 2024. The co-venturer, KRKA d.d., Novo mesto, Slovenia, will also invest approximately EUR 10,200,000. The existing 51:49 shareholding ratio between KRKA d.d. and Laurus Labs Limited will remain unchanged.

KRKA Pharma has an authorised share capital of INR 370,00,00,000 divided into 37,00,00,000 equity shares of INR 10 each, and paid-up share capital of INR 315,00,00,000 divided into 31,50,00,000 equity shares of INR 10 each. The turnover for 2025-26 was INR 10.47 million. The funds will be utilised for KRKA's capital expenditure plan to establish a manufacturing facility.

Closure of German Subsidiary

The Board approved the voluntary closure of Laurus Generics GmbH, a step-down wholly owned subsidiary in Germany, in accordance with applicable German laws. The subsidiary reported nil revenue for the financial year ended March 31, 2026, and maintained a negative net worth of EUR 10,53,091.

The closure will not have any material impact on the company or its financials. The process will be completed subject to regulatory approvals in Germany, and the company will inform the exchanges upon completion of the closure formalities.